CO6321255A2 - "inhibidores de ciclopropil polimerasa" - Google Patents

"inhibidores de ciclopropil polimerasa"

Info

Publication number
CO6321255A2
CO6321255A2 CO10161808A CO10161808A CO6321255A2 CO 6321255 A2 CO6321255 A2 CO 6321255A2 CO 10161808 A CO10161808 A CO 10161808A CO 10161808 A CO10161808 A CO 10161808A CO 6321255 A2 CO6321255 A2 CO 6321255A2
Authority
CO
Colombia
Prior art keywords
hydrogen
alkyl
compounds
cyclopropil
polymerase inhibitors
Prior art date
Application number
CO10161808A
Other languages
English (en)
Inventor
Tim Hugo Maria Jonckers
Pierre Jean-Marie Raboisson
Koen Vandyck
Original Assignee
Medivir Ab Centocor Ortho Biotech Products L P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41095413&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6321255(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medivir Ab Centocor Ortho Biotech Products L P filed Critical Medivir Ab Centocor Ortho Biotech Products L P
Publication of CO6321255A2 publication Critical patent/CO6321255A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)

Abstract

Los compuestos de fórmula I:donde:R2 es hidrógeno o alquilo C1-C4;R3 y R4 son hidrógeno, -C(=O)R5, o -C(=O)CHR6-NH2; o R3 es hidrógeno y es un éster de monofosfato, difosfato, o trifosfato; oR3 es hidrógeno, -C(=O)CHR5, o -C(=O)CHR6-NH2 y R4 escada R5 es hidrógeno, alquilo C1-C6, o cicloalquilo C3-C7;R6 es hidrógeno o alquilo C1-C6; R7 es fenilo opcionalmente sustituido; naftilo; o indolilo;R8 y R8' son hidrógeno, alquilo C1-C6, bencilo; oR8 y R8' combinados forman cicloalquilo C3-C7;R9 es alquilo C1-C6, bencilo, o fenilo opcionalmente sustituido;siempre que R2, R3 y R4 no sean todos hidrógeno;o su sal o solvato aceptable para uso farmacéutico;formulaciones farmacéuticas con los compuestos I; el uso de compuestos I, incluyendo los compuestos de fórmula I donde R2, R3 y R4 son todos hidrógeno, como inhibidores del VHC.
CO10161808A 2008-07-01 2010-12-23 "inhibidores de ciclopropil polimerasa" CO6321255A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08159396 2008-07-01
EP08171005 2008-12-08

Publications (1)

Publication Number Publication Date
CO6321255A2 true CO6321255A2 (es) 2011-09-20

Family

ID=41095413

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10161808A CO6321255A2 (es) 2008-07-01 2010-12-23 "inhibidores de ciclopropil polimerasa"

Country Status (29)

Country Link
US (1) US8431588B2 (es)
EP (1) EP2141172B1 (es)
JP (1) JP5624029B2 (es)
KR (1) KR20110038683A (es)
CN (2) CN102083845B (es)
AP (1) AP2010005505A0 (es)
AR (1) AR072428A1 (es)
AU (1) AU2009266004B2 (es)
BR (1) BRPI0913643A2 (es)
CA (1) CA2729316A1 (es)
CL (1) CL2010001634A1 (es)
CO (1) CO6321255A2 (es)
DK (1) DK2141172T3 (es)
EA (1) EA022754B1 (es)
EC (1) ECSP10010725A (es)
ES (1) ES2396803T3 (es)
HK (1) HK1226080A1 (es)
HR (1) HRP20121068T1 (es)
IL (1) IL209932A (es)
MX (1) MX2010014493A (es)
NI (1) NI201000231A (es)
PL (1) PL2141172T3 (es)
PT (1) PT2141172E (es)
SI (1) SI2141172T1 (es)
SV (1) SV2010003779A (es)
TW (1) TW201012814A (es)
UY (1) UY31950A (es)
WO (1) WO2010000459A1 (es)
ZA (1) ZA201009294B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2337809T3 (es) * 2008-09-08 2017-12-30
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
TW201201815A (en) * 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
MX2013007698A (es) 2010-12-30 2013-08-15 Abbvie Inc Inhibidores de serina proteasa de hepatitis c macrociclicos de fenantridina.
EP2658859A4 (en) 2010-12-30 2014-07-30 Enanta Pharm Inc MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
JP5845841B2 (ja) 2011-11-18 2016-01-20 東芝ライテック株式会社 照明制御装置
CA2864098A1 (en) 2012-02-14 2013-08-22 University Of Georgia Research Foundation, Inc. Spiro[2.4]heptanes for treatment of flaviviridae infections
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
MY190867A (en) 2015-03-06 2022-05-13 Atea Pharmaceuticals Inc ? -d-2'-deoxy-2'-?-fluoro-2'- ? -c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
RU2590952C1 (ru) * 2015-05-26 2016-07-10 Вячеслав Энгельсович Семёнов Средство гепатопротекторного действия
LU100724B1 (en) 2016-07-14 2018-07-31 Atea Pharmaceuticals Inc Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
EA037868B1 (ru) 2016-09-07 2021-05-28 Атеа Фармасьютикалс, Инк. 2'-замещенные-n6-замещенные пуриновые нуклеотиды для лечения вызванных рнк-вирусом заболеваний
JP7066728B2 (ja) 2017-02-01 2022-05-13 アテア ファーマシューティカルズ， インコーポレイテッド Ｃ型肝炎ウイルスの治療のためのヌクレオチドヘミ硫酸塩
CN112351799A (zh) 2018-04-10 2021-02-09 阿堤亚制药公司 具有硬化的hcv感染患者的治疗
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE417836T1 (de) 1992-12-29 2009-01-15 Abbott Lab Verfahren und intermediate zur herstellung von retroviralen proteasehemmern
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
GB0114286D0 (en) * 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
WO2004002999A2 (en) * 2002-06-28 2004-01-08 Idenix (Cayman) Limited Modified 2' and 3' -nucleoside produgs for treating flaviridae infections
ATE490788T1 (de) * 2003-04-25 2010-12-15 Gilead Sciences Inc Antivirale phosphonate analoge
CA2577526A1 (en) * 2004-08-23 2006-03-02 Joseph Armstrong Martin Antiviral 4'-azido-nucleosides
AP2009004812A0 (en) 2006-10-10 2009-04-30 Medivir Ab HCV nucleoside inhibitor

Also Published As

Publication number Publication date
WO2010000459A1 (en) 2010-01-07
AP2010005505A0 (en) 2010-12-31
AU2009266004B2 (en) 2014-01-30
MX2010014493A (es) 2011-05-19
ES2396803T3 (es) 2013-02-27
DK2141172T3 (da) 2013-01-21
IL209932A (en) 2013-12-31
EA022754B1 (ru) 2016-02-29
AR072428A1 (es) 2010-08-25
JP5624029B2 (ja) 2014-11-12
US20110092460A1 (en) 2011-04-21
CN105693794A (zh) 2016-06-22
EA201170118A1 (ru) 2011-06-30
US8431588B2 (en) 2013-04-30
CA2729316A1 (en) 2010-01-07
CL2010001634A1 (es) 2011-08-05
JP2011526270A (ja) 2011-10-06
CN102083845A (zh) 2011-06-01
IL209932A0 (en) 2011-02-28
UY31950A (es) 2010-01-29
KR20110038683A (ko) 2011-04-14
PL2141172T3 (pl) 2013-03-29
BRPI0913643A2 (pt) 2015-11-24
EP2141172A1 (en) 2010-01-06
NI201000231A (es) 2011-09-03
SV2010003779A (es) 2011-02-08
HRP20121068T1 (hr) 2013-01-31
HK1226080A1 (zh) 2017-09-22
EP2141172B1 (en) 2012-10-24
TW201012814A (en) 2010-04-01
ZA201009294B (en) 2012-06-27
CN102083845B (zh) 2016-09-14
PT2141172E (pt) 2013-01-14
AU2009266004A1 (en) 2010-01-07
ECSP10010725A (es) 2011-04-29
SI2141172T1 (sl) 2013-02-28

Similar Documents

Publication Publication Date Title
CO6321255A2 (es) "inhibidores de ciclopropil polimerasa"
UY32308A (es) Nucleótidos uracil ciclopropílicos
CO6440533A2 (es) Nucleósidos espiro oxetánicos uracílicos
AR083676A1 (es) Compuestos heterociclicos, útiles como inhibidores de quinasa y composiciones farmaceuticas que los contienen
ECSP109932A (es) Compuestos de biciclolactama sustituida
PE20130187A1 (es) Bis(difluorometil) pirazoles como fungicidas
AR091156A1 (es) Nucleosidos de espirooxetano de uracilo
CO6210729A2 (es) Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona procedimientos para su preparacion y su uso como agente farmaceutico
AR087754A1 (es) 6h-tieno[3,2,-f][1,2,4]triazolo[4,3-a][1,4]diazepina
CO6290658A2 (es) Derivados de azetidina y ciclobutano como inhibidores de jack
AR075583A1 (es) Derivados de isoxazol/o-piridina con eslabon etilo o etenilo
CO6230986A2 (es) Compuesto de 4-piridinona y su uso para cancer
UY30391A1 (es) Compuesto de oximilo aciclico inhibidores de proteasa de hepatitis c
AR072803A1 (es) Tetrahidrocinolinas como inhibidores de la 11- beta -hsd1 para la diabetes
AR085428A1 (es) (3r,4r)-4-ciano-3,4-difenilbutanoatos sustituidos, procedimiento para su preparacion y su uso como herbicidas y reguladores de crecimiento de plantas
AR088414A1 (es) Derivados sustituidos de indol
AR085542A1 (es) Compuestos de azaespirodecanona como inhibidores de hsl
AR098854A1 (es) 5-aril-1-imino-1-oxo-[1,2,4]tiadiazinas
TH112183B (th) สารยับยั้งไซโคลโพรพิล พอลิเมอเรส
AR098583A1 (es) Compuesto de sulfonamida de benzotiofeno, composición farmacéutica que lo comprende y su uso para la preparación de dicha composición
AR112803A2 (es) Derivados de piperazina como moduladores de piruvato quinasa m2 (pkm2)
UY31262A1 (es) Compuestos de biciclolactama sustituida
CU20100017A7 (es) Compuestos de biciclolactama sustituida
TH112183A (th) สารยับยั้งไซโคลโพรพิล พอลิเมอเรส
AR079266A1 (es) Derivados de azabiciclo[3.2.0]hept-6ilo, procedimiento de preparacion de los mismos, intermediarios de sintesis, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas,tales como alzheimer.

Legal Events

Date Code Title Description
FA Application withdrawn